Bacteriophage-Mediated Activation of Silent Gene Clusters
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional methods for discovering novel natural products are hindered by transcriptionally silent or poorly expressed gene clusters in microbial organisms, limiting the discovery of therapeutic and commercial natural products due to inefficiencies and high costs.
Innovation Solution
The use of bacteriophages carrying specific transcription factors, such as Streptomyces Antibiotic Regulatory Proteins (SARP), to infect bacterial cells and activate transcriptionally silent or poorly expressed genes or gene clusters, enabling the expression of natural products that would otherwise not be produced under laboratory conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional fermentation and fractionation methods are used for natural product discovery, then the process is straightforward and easy to perform, but a significant portion of biosynthetic gene clusters remain transcriptionally silent and are not producing the encoded molecule, limiting discovery
Solution Approach 1:
The patent introduces bacteriophages that deliver transcription factors to alter the transcriptional state of silent gene clusters. By changing the regulatory parameters (adding exogenous transcription factors like SARP proteins), the system transitions from silent to active gene expression, thereby increasing natural product yield without complicating the overall fermentation process
Solution Approach 2:
The patent uses bacteriophages as intermediary vectors to deliver transcription factors into bacterial cells. These phage-mediated transcription factors act as mediators that bridge the gap between silent gene clusters and active transcription, enabling expression of natural products that would otherwise remain unproduced under standard laboratory conditions
2Ease of manufacture
If conventional transformation methods (conjugation and/or protoplasting) are used for Actinomycetes, then gene integration can be achieved for few species, but the majority of Actinomycetes have not been successfully transformed and the time needed for protocol modification for each species is extremely limiting
Solution Approach 1:
The patent employs bacteriophages as a universal transformation vector that can infect and deliver genetic material across diverse Actinomycetes species. Unlike species-specific conjugation or protoplasting methods, the phage-based system provides broad host range and adaptability, enabling efficient gene delivery to majority of Actinomycetes without requiring extensive protocol customization for each species
3Reliability
If extensive experimentation is conducted to modify transformation protocols for each Streptomyces species, then species-specific transformation efficiency can be improved, but the time needed becomes extremely limiting and costs increase
Solution Approach 1:
The patent utilizes the natural infection capability of bacteriophages to automatically deliver transcription factors into target bacterial cells. The phage system performs the transformation function autonomously through its natural life cycle, eliminating the need for manual protocol optimization and extensive experimental iteration for each species, thereby reducing both time and resource investment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the high-throughput and cost-effective activation of previously silent gene clusters across various bacterial strains, increasing the diversity and availability of natural products for therapeutic and commercial use.
Implementation Method 1
a bacteriophage comprising one or more transcription factors or a library of bacteriophages, wherein at least a subset of the bacteriophages each comprise a unique transcription factor
Data Source
AI summary
The disclosure provides compositions and methods for producing natural products in microorganisms that are otherwise unexpressed, poorly expressed or poorly transcribed. In particular aspects, the disclosure provides compositions and methods for activating a silent gene or gene cluster with a bacteriophage and/or Streptomyces Antibiotic Regulatory Protein (SARP) transcription factor.